BK Virus Nephropathy: Prevalence, Impact and Management Strategies

References

• Gardner SD, Field AM, Coleman DV, et al. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet. 1971;1(7712):1253–1257. doi:10.1016/S0140-6736(71)91776-44104714
   PubMed Web of Science ®Google Scholar
• Chatterjee M, Weyandt TB, Frisque RJ. Identification of archetype and rearranged forms of BK virus in leukocytes from healthy individuals. J Med Virol. 2000;60(3):353–362. doi:10.1002/(SICI)1096-9071(200003)60:3<353::AID-JMV16>3.0.CO;2-R10630970
   PubMed Web of Science ®Google Scholar
• Flaegstad T, Ronne K, Filipe AR, et al. Prevalence of anti BK virus antibody in Portugal and Norway. Scan J Infectious Dis. 1989;21(2):145–147. doi:10.3109/00365548909039961
   PubMed Web of Science ®Google Scholar
• Stolt A, Sasnauskas K, Koskela P, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol. 2003;84(Pt 6):1499–1504. doi:10.1099/vir.0.18842-012771419
   PubMed Web of Science ®Google Scholar
• Goudsmit J, Wertheim-van Dillen P, van Strien A, et al. The role of BK virus in acute respiratory tract disease and the presence of BKV DNA in tonsils. J Med Virol. 1982;10(2):91–99. doi:10.1002/jmv.18901002036292361
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation. 2005;79(10):1277–1286. doi:10.1097/01.TP.0000156165.83160.0915912088
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Steiger J. Polyomavirus BK. Lancet Infect Dis. 2003;3(10):611–623. doi:10.1016/S1473-3099(03)00770-914522260
   PubMed Web of Science ®Google Scholar
• Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant. 2004;4(12):2082–2092. doi:10.1046/j.1600-6143.2004.00603.x15575913
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Randhawa P. AST infectious diseases community of practice. BK virus in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S136–S146.20070673
   PubMed Web of Science ®Google Scholar
• Sar A, Worawichawong S, Benediktsson H, et al. Interobserver agreement for polyomavirus nephropathy grading in renal allografts using the working proposal from the 10th Banff Conference on Allograft Pathology. Hum Pathol. 2011;42(12):2018–2024. doi:10.1016/j.humpath.2011.03.00821733554
   PubMed Web of Science ®Google Scholar
• Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272–283. doi:10.1111/ajt.1259024472190
   PubMed Web of Science ®Google Scholar
• Masutani K, Shapiro R, Basu A, et al. The Banff 2009 working proposal for polyomavirus nephropathy: a critical evaluation of its utility as a determinant of clinical outcome. Am J Transplant. 2012;12(4):907–918. doi:10.1111/j.1600-6143.2012.03993.x22390378
   PubMed Web of Science ®Google Scholar
• Adam BA, Kikic Z, Wagner S, et al. Intragraft gene expression in native kidney BK virus nephropathy versus T cell-mediated rejection: prospects for molecular diagnosis and risk prediction [published online ahead of print, 2020 May 5]. Am J Transplant. 2020. doi:10.1111/ajt.15980
   Web of Science ®Google Scholar
• Sharif A, Alachkar N, Bagnasco S, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7:1320–1327. doi:10.2215/CJN.0077011222626962
   PubMed Web of Science ®Google Scholar
• Boan P, Hewison C, Swaminathan R, et al. Optimal use of plasma and urine BK viral loads for screening and predicting BK nephropathy. BMC Infect Dis. 2016;16:342. doi:10.1186/s12879-016-1652-627448566
   PubMed Web of Science ®Google Scholar
• Gabardi S, Townsend K, Martin ST, et al. Evaluating the impact of pre-transplant desensitization utilizing a plasmapheresis and low-dose intravenous immunoglobulin protocol on BK viremia in renal transplant recipients. Transpl Infect Dis. 2013;15:361–368. doi:10.1111/tid.1208723647907
   PubMed Web of Science ®Google Scholar
• Nickeleit V, Singh HK, Randhawa P, et al. The Banff working group classification of definitive polyomavirus nephropathy: morphologic definitions and clinical correlations. J Am Soc Nephrol. 2018;29:680–693. doi:10.1681/ASN.201705047729279304
   PubMed Web of Science ®Google Scholar
• Leung AY, Chan M, Tang SC, et al. Real-time quantitative analysis of polyoma BK viremia and viruria in renal allograft recipients. J Virol Meth. 2002;103(1):51–56. doi:10.1016/S0166-0934(01)00447-5
   Web of Science ®Google Scholar
• Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med. 2002;347(7):488–496. doi:10.1056/NEJMoa02043912181403
   PubMed Web of Science ®Google Scholar
• Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immuno-suppression reduction. Am J Transplant. 2005;5(3):582–594. doi:10.1111/j.1600-6143.2005.00742.x15707414
   PubMed Web of Science ®Google Scholar
• Hirsch HH. BK virus: opportunity makes a pathogen. Clin Infect Dis. 2005;41(3):354–360. doi:10.1086/43148816007533
   PubMed Web of Science ®Google Scholar
• Kuypers DR. Management of polyomavirus-associated nephro-pathy in renal transplant recipients. Nat Rev Nephrol. 2012;8(7):390–402. doi:10.1038/nrneph.2012.6422508181
   PubMed Web of Science ®Google Scholar
• Van Aalderen MC, Heutinck KM, Huisman C, et al. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. Neth J Med. 2012;70(4):172–183.22641625
   PubMed Web of Science ®Google Scholar
• Sharma R, Tzetzo S, Patel S, et al. BK virus in kidney transplant: current concepts, recent advances, and future directions. Exp Clin Transplant. 2016;14(4):377–384. doi:10.6002/ect.2016.003027267780
   PubMed Web of Science ®Google Scholar
• Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. JASN Jul. 2017;28(7):2221–2232. doi:10.1681/ASN.2016091034
   Web of Science ®Google Scholar
• Sawinski D, Forde KA, Trofe-Clark J, et al. Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies. J Am Soc Nephrol. 2015;26:966–975. doi:10.1681/ASN.201401011925255921
   PubMed Web of Science ®Google Scholar
• Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293–307. doi:10.1111/ajt.1462529243394
   PubMed Web of Science ®Google Scholar
• Hariharan S, Cohen EP, Vasudev B, et al. BK virus-specific antibodies and BKV DNA in renal transplant recipients with BKV nephritis. Am J Transplant. 2005;5(11):2719–2724. doi:10.1111/j.1600-6143.2005.01080.x16212632
   PubMed Web of Science ®Google Scholar
• Chen Y, Trofe J, Gordon J, et al. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol. 2006;80(7):3495–3505. doi:10.1128/JVI.80.7.3495-3505.200616537617
   PubMed Web of Science ®Google Scholar
• Drummond JE, Shah KV, Donnenberg AD. Cell-mediated immune responses to BK virus in normal individuals. J Med Virol. 1985;17(3):237–247. doi:10.1002/jmv.18901703052999323
   PubMed Web of Science ®Google Scholar
• Batal I, Zeevi A, Heider A, et al. Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol. 2008;129(4):587–591. doi:10.1309/23YGPB1E758ECCFP18343786
   PubMed Web of Science ®Google Scholar
• Binggeli S, Egli A, Dickenmann M, et al. BKV replication and cellular immune responses in renal transplant recipients. Am J Transplant. 2006;6(9):2218–9;author reply 20. doi:10.1111/j.1600-6143.2006.01460.x
   Web of Science ®Google Scholar
• Prosser SE, Orentas RJ, Jurgens L, et al. Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of BK virus nephritis. Transplantation. 2008;85(2):185–192. doi:10.1097/TP.0b013e31815fef5618212622
   PubMed Web of Science ®Google Scholar
• Comoli P, Azzi A, Maccario R, et al. Polyomavirus BK-specific immunity after kidney transplantation. Transplantation. 2004;78(8):1229–1232. doi:10.1097/01.TP.0000137932.44791.D315502726
   PubMed Web of Science ®Google Scholar
• Comoli P, Binggeli S, Ginevri F, et al. Polyomavirus-associated nephropathy: update on BK virus-specific immunity. Transpl Infect Dis. 2006;8(2):86–94. doi:10.1111/j.1399-3062.2006.00167.x16734631
   PubMed Web of Science ®Google Scholar
• Comoli P, Cioni M, Basso S, et al. Immunity to polyomavirus BK infection: immune monitoring to regulate the balance between risk of BKV nephropathy and induction of alloimmunity. Clin Dev Immunol. 2013;2013:256923. doi:10.1155/2013/25692324000288
   PubMedGoogle Scholar
• Schachtner T, Muller K, Stein M, et al. BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant. 2011;11(11):2443–2452. doi:10.1111/j.1600-6143.2011.03693.x21831150
   PubMed Web of Science ®Google Scholar
• Schachtner T, Stein M, Sefrin A, et al. Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation. Transplant Int. 2014;27(3):290–301. doi:10.1111/tri.12251
   PubMed Web of Science ®Google Scholar
• Smith JM, McDonald RA, Finn LS, et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant. 2004;4(12):2109–2117. doi:10.1111/j.1600-6143.2004.00629.x15575916
   PubMed Web of Science ®Google Scholar
• Sood P, Senanayake S, Sujeet K, et al. Donor and recipient BKV- specific IgG antibody and post transplantation BKV infection: a prospective single-center study. Transplantation. 2013;95(6):896–902. doi:10.1097/TP.0b013e318282ba8323511214
   PubMed Web of Science ®Google Scholar
• Awadalla Y, Randhawa P, Ruppert K, et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant. 2004;4(10):1691–1696. doi:10.1111/j.1600-6143.2004.00563.x15367226
   PubMed Web of Science ®Google Scholar
• Prince O, Savic S, Dickenmann M, et al. Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant. 2009;24(3):1024–1033. doi:10.1093/ndt/gfn67119073658
   PubMed Web of Science ®Google Scholar
• Ramos E, Drachenberg CB, Portocarrero M, et al. BK virus nephropathy diagnosis and treatment: experience at the University of Maryland Renal Transplant Program. Clin Transplant. 2002;143–153.
   Google Scholar
• Dalianis T, Eriksson B-M, Felldin M, et al. Management of BK-virus infection – Swedish recommendations. Infect Dis. 2019;51(7):479–484. doi:10.1080/23744235.2019.1595130
   PubMed Web of Science ®Google Scholar
• Chen XT, Li J, Deng RH, et al. The therapeutic effect of switching from tacrolimus to low-dose cyclosporine A in renal transplant recipients with BK virus nephropathy. Biosci Rep. 2019;39(2):BSR20182058. doi:10.1042/BSR2018205830737303
   PubMed Web of Science ®Google Scholar
• Gard L, van Doesum W, Niesters HGM, et al. A delicate balance between rejection and BK polyomavirus associated nephropathy; a retrospective cohort study in renal transplant recipients. PLoS One. 2017;12(6):e0178801. doi:10.1371/journal.pone.017880128609473
   PubMed Web of Science ®Google Scholar
• Bowman LJ, Brueckner AJ, Doligalski CT. The role of mTOR inhibitors in the management of viral infections: a review of current literature. Transplantation. 2018;102:S50–S59. doi:10.1097/TP.000000000000177729369973
   PubMed Web of Science ®Google Scholar
• Bussalino E, Marsano L, Parodi A, et al. Everolimus for BKV nephropathy in kidney transplant recipients: a prospective, controlled study. J Nephrol. 2020. doi:10.1007/s40620-020-00777-2
   Web of Science ®Google Scholar
• Josephson MA, Gillen D, Javaid B, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation. 2006;81(5):704–710. doi:10.1097/01.tp.0000181149.76113.5016534472
   PubMed Web of Science ®Google Scholar
• Williams JW, Javaid B, Kadambi PV, et al. Leflunomide for polyomavirus type BK nephropathy. N Engl J Med. 2005;352(11):1157–1158. doi:10.1056/NEJM20050317352112515784677
   PubMed Web of Science ®Google Scholar
• Williams JW, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation. Transplantation. 2002;73(3):358–366. doi:10.1097/00007890-200202150-0000811884931
   PubMed Web of Science ®Google Scholar
• Hirsch HH, Randhawa P. AST infectious diseases community of practice. BK polyomavirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):179–188.
   PubMed Web of Science ®Google Scholar
• Kadambi PV, Josephson MA, Williams J, et al. Treatment of refractory BK virus-associated nephropathy with cidofovir. Am J Transplant. 2003;3(2):186–191. doi:10.1034/j.1600-6143.2003.30202.x12614296
   PubMed Web of Science ®Google Scholar
• Keller LS, Peh CA, Nolan J, et al. BK transplant nephropathy successfully treated with cidofovir. Nephrol Dial Transplant. 2003;18(5):1013–1014. doi:10.1093/ndt/gfg06112686681
   PubMed Web of Science ®Google Scholar
• Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant. 2005;5(8):1997–2004. doi:10.1111/j.1600-6143.2005.00980.x15996251
   PubMed Web of Science ®Google Scholar
• Reisman L, Habib S, McClure GB, et al. Treatment of BK virus-associated nephropathy with CMX001 after kidney transplantation in a young child. Pediatr Transplant. 2014;18:E227–E231. doi:10.1111/petr.1234025174393
   PubMed Web of Science ®Google Scholar
• Papanicolaou GA, Lee YJ, Young JW, et al. Brincidofovir for polyomavirus-associated nephropathy after allogeneic hema-topoietic stem cell transplantation. Am J Kidney Dis. 2015;65(5):780–784. doi:10.1053/j.ajkd.2014.11.02025600489
   PubMed Web of Science ®Google Scholar
• Randhawa P, Pastrana DV, Zeng G, et al. Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK. Am J Transplant. 2015;15(4):1014‐1020. doi:10.1111/ajt.13083
   Web of Science ®Google Scholar
• Sener A, House AA, Jevnikar AM, et al. Intravenous immu-noglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation. 2006;81(1):117–120. doi:10.1097/01.tp.0000181096.14257.c216421486
   PubMed Web of Science ®Google Scholar
• Vu D, Shah T, Ansari J, et al. Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients. Transplant Proc. 2015;47(2):394‐398. doi:10.1016/j.transproceed.2015.01.012
   Web of Science ®Google Scholar
• Moon J, Chang Y, Shah T, et al. Effects of intravenous immunoglobulin therapy and Fc gamma receptor polymorphisms on BK virus nephropathy in kidney transplant recipients [published online ahead of print, 2020 Apr 23]. Transpl Infect Dis. 2020:e13300. doi:10.1111/tid.13300.32323406
   PubMed Web of Science ®Google Scholar
• Gabardi S, Waikar SS, Martin S, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol. 2010;5(7):1298–1304. doi:10.2215/CJN.0826110920507960
   PubMed Web of Science ®Google Scholar
• Sharma BN, Li R, Bernhoff E, et al. Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antiviral Res. 2011;92(1):115–123. doi:10.1016/j.antiviral.2011.07.01221798289
   PubMed Web of Science ®Google Scholar
• Knoll GA, Humar A, Fergusson D, et al. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. JAMA. 2014;312(20):2106–2114. doi:10.1001/jama.2014.1472125399012
   PubMed Web of Science ®Google Scholar